FDA or Emergent BioSolutions official announcements

Emergent BioSolutions Secures $41.9 Million BARDA Contract Option for Ebola Treatment Development

Sep 13, 2024, 10:48 AM

Emergent BioSolutions has been awarded a research and development option valued at $41.9 million to further the development and scale-up of its monoclonal antibody treatment, Ebanga™, for Ebola virus infection. The BARDA contract option will cover steps such as scale-up process validation, commercial readiness, and post-licensure commitments, including technology transfer and submission of a supplemental Biologics License Application (BLA). This funding aims to enhance the advanced development and procurement of Ebanga™ treatment.